您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (4): 123-127.doi: 10.6040/j.issn.1671-7554.0.2021.1474

• • 上一篇    

Barth综合征1例报道

任红,王伟,林岩,娄建伟,纪坤乾,赵玉英,焉传祝   

  • 发布日期:2022-04-22
  • 通讯作者: 娄建伟. E-mail:25562452@qq.com
  • 基金资助:
    国家自然科学基金(82171394,82071412)

A case report of Barth syndrome

REN Hong, WANG Wei, LIN Yan, LOU Jianwei, JI Kunqian, ZHAO Yuying, YAN Chuanzhu   

  1. Department of Neurology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2022-04-22

摘要: 目的 对1例TAZ基因突变的Barth综合征(BTHS)患者进行临床表现、影像学特征、肌肉病理、基因测序分析,以提高临床医生对此病的认识。 方法 收集1例BTHS患者的临床及实验室资料进行分析,并通过复习相关文献对疾病进行简要总结。 结果 患者为14岁男性,自幼生长发育迟缓,因四肢无力2个月余入院,查体示双侧转颈、耸肩力弱及四肢肌力减弱。血常规示中性粒细胞计数减少;尿有机酸检测示3-甲基戊烯二酸升高。影像学检查示双侧臀大肌及双侧胫骨干骺端周围肌肉FS T2WI异常信号。肌肉病理示轻度肌源性损害。基因检测证实患者及其母亲为TAZ基因c.589G>A突变。 结论 Barth综合征是一种具有临床和遗传异质性的疾病,其发病形式多样。当患者出现不明原因的中性粒细胞减少或心肌病变等表现,应考虑该病可能。早期诊断和对症支持治疗可提高患者的生存质量。

关键词: Barth综合征, TAZ基因, 突变, 心磷脂

Abstract: Objective To investigate the clinical manifestations, imaging features, muscle pathology and genetic analysis of a patient presenting Barth syndrome(BTHS)with TAZ gene mutation, so as to improve clinician’s understanding of the disease. Methods Clinical and laboratory data of a patient with BTHS were collected and analyzed, and relevant literature was reviewed. Results The patient was a 14-year-old boy presenting with growth retardation since childhood. He was admitted to our hospital due to weakness of limbs for more than two months. Physical examination showed bilateral weakness in trapezius, sternocleidomastoid muscles and limbs. Blood routine examination indicated a decrease in neutrophil count. Urine organic acid analysis revealed elevated 3-methylglutaconicaciduria. Muscle MRI showed abnormal signals on FS T2WI(fat suppression T2 weighted imaging)in both gluteus maximus muscles and muscles around the tibial epiphysis. Muscle pathology showed mild myogenic lesion. Genetic analysis confirmed that the patient and his mother carried mutation c.589G>A in the TAZ gene. Conclusion Barth syndrome is a clinically and genetically heterogeneous disorder with various onset forms. When patients present with inexplicable decreased neutrophils or myocardial involvement, BTHS should be considered. Early diagnosis, symptomatic treatment and supportive care can improve the quality of life for patients.

Key words: Barth syndrome, TAZ gene, Mutation, Cardiolipin

中图分类号: 

  • R746.9
[1] Vreken P, Valianpour F, Nijtmans LG, et al. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome [J]. Biochem Biophys Res Commun, 2000, 279(2): 378-382.
[2] Miller PC, Ren M, Schlame M, et al. A bayesian analysis to determine the prevalence of Barth syndrome in the pediatric population [J]. J Pediatr, 2020, 217: 139-144. doi: 10.1016/j.jpeds.2019.09.074.
[3] Clarke SL, Bowron A, Gonzalez IL, et al. Barth syndrome [J]. Orphanet J Rare Dis, 2013, 8: 23. doi: 10.1186/1750-1172-8-23.
[4] 宋金青, 马艳艳, 丁圆, 等. Barth综合征导致幼儿心内膜弹力纤维增生症的临床特点及其TAZ基因突变[J]. 中华妇幼临床医学杂志(电子版), 2016, 12(5): 535-539. SONG Jinqing, MA Yanyan, DING Yuan, et al. Clinicai characteristics and TAZgene mutation of an infant with endocardial fibroelastosis due to Barth syndrome[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2016, 12(5): 535-539.
[5] Chin TK, Perloff JK, Williams RG, et al. Isolated noncompaction of left ventricular myocardium. A study of eight cases [J]. Circulation, 1990, 82(2): 507-513.
[6] Roberts AE, Nixon C, Steward CG, et al. The Barth syndrome registry: distinguishing disease characteristics and growth data from a longitudinal study [J]. Am J Med Genet a, 2012, 158A(11): 2726-2732.
[7] 石琳, 傅立军, 黄美容, 等. Barth综合征3例临床表现及基因突变分析[J]. 临床儿科杂志, 2015, 33(7): 614-617.
[8] Schlame M, Xu Y. The Function of tafazzin, a mitochondrial phospholipid-lysophospholipid acyltransferase [J]. J Mol Biol, 2020, 432(18): 5043-5051.
[9] Houtkooper RH, Vaz FM. Cardiolipin, the heart of mitochondrial metabolism [J]. Cell Mol Life Sci, 2008, 65(16): 2493-2506.
[10] Takeda A, Sudo A, Yamada M, et al. Eponym: Barth syndrome [J]. Eur J Pediatr, 2011, 170(11):1365-1367.
[11] Aprikyan AA, Khuchua Z. Advances in the understanding of Barth syndrome [J]. Br J Haematol, 2013, 161(3): 330-338.
[12] Zegallai HM, Hatch GM. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets [J]. Mol Cell Biochem, 2021, 476(3): 1605-1629.
[13] Dudek J, Cheng IF, Chowdhury A, et al. Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome [J]. EMBO Mol Med, 2016, 8(2): 139-154.
[14] Schwall CT, Greenwood VL, Alder NN. The stability and activity of respiratory Complex II is cardiolipin-dependent [J]. Biochim Biophys Acta, 2012, 1817(9): 1588-1596.
[15] Gill AJ. Succinate dehydrogenase(SDH)-deficient neoplasia [J]. Histopathology, 2018, 72(1): 106-116.
[16] Valianpour F, Wanders RJ, Overmars H, et al. Linoleic acid supplemention of Barth syndrome fibroblasts restores cardiolipin levels: Implications for treatment [J]. J Lipid Res, 2003, 44(3): 560-566.
[17] Huang Y, Powers C, Moore V, et al. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome [J]. Orphanet J Rare Dis, 2017, 12(1): 49.
[18] Wang S, Li Y, Xu Y, et al. AAV gene therapy prevents and reverses heart failure in a murine knockout model of barth syndrome [J]. Circ Res, 2020, 126(8): 1024-1039.
[19] Suzuki-Hatano S, Saha M, Rizzo SA, et al. AAV-Mediated TAZ gene replacement restores mitochondrial and cardioskeletal function in barth syndrome [J]. Hum Gene Ther, 2019, 30(2): 139-154.
[20] Povsic TJ, O’Connor CM, Henry T, et al. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction [J]. Am Heart J, 2011, 162(4): 654-662.
[21] He Q, Harris N, Ren J, et al. Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in cardiac myocytes [J]. Oxid Med Cell Longev, 2014, 2014: 654198. doi:10.1155/2014/654198.
[1] 薛美娟,石艳,邵琳琳,王琳,张昀,张阿敏. 遗传性血栓性血小板减少性紫癜1例并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 121-124.
[2] 亓梦雨,周敏然,孙洺山,李世洁,陈春燕. T大颗粒淋巴细胞白血病合并原发性骨髓纤维化1例[J]. 山东大学学报 (医学版), 2022, 60(2): 118-120.
[3] 潘鹏飞,徐立升,纪坤乾,王得翔,李玉. 以呼吸衰竭起病的线粒体肌病1例及文献回顾[J]. 山东大学学报 (医学版), 2022, 60(2): 54-59.
[4] 史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116.
[5] 赵怀龙,吕燕,赵红,赵宝添,韩莹,潘晶,丁小满,王春荣,韩秀云,刘岚铮. 济南市人鼻病毒B83型基因组特征及分子变异分析[J]. 山东大学学报 (医学版), 2021, 59(5): 68-72, 81.
[6] 孙宇,陈娜,马爱华. SLC35A2基因突变致先天性糖基化障碍1例[J]. 山东大学学报 (医学版), 2021, 59(4): 113-116.
[7] 黄秀丽,刘丙菊,孙立锋. PIK3CD基因突变致PI3Kδ过度活化综合征1例并文献复习[J]. 山东大学学报 (医学版), 2021, 59(3): 107-112.
[8] 王正阳,夏艳,师凯旋,陶琨,王小杰. 曲美替尼在卵巢癌中对PAX8的表达作用[J]. 山东大学学报 (医学版), 2021, 59(10): 23-29.
[9] 胡思翠,孙清,王一冰,孙莉莉,隋炎希,李堂. Bartter综合征二例家系报告与CLCNKB基因突变分析[J]. 山东大学学报 (医学版), 2020, 1(9): 64-70.
[10] 徐继禧,陈伟健. 髓内弥漫性中线胶质瘤伴H3 K27M突变1例[J]. 山东大学学报 (医学版), 2020, 1(7): 96-101.
[11] 刘贺,刘福强,侯新国,陈丽. CYP11B1基因新突变致11β-羟化酶缺陷症1例家系研究[J]. 山东大学学报(医学版), 2017, 55(9): 85-89.
[12] 卢敏, 陈昀, 丁卜同, 常亚丽, 周亚伟, 赵爱平, 郭农建. 山东省乙型血友病患者的基因检测及分析[J]. 山东大学学报(医学版), 2015, 53(3): 87-92.
[13] 孙杰,牟晓燕,董雪丽. 舒尼替尼与吉西他滨联合及序贯应用对K-RAS突变A549细胞的影响[J]. 山东大学学报(医学版), 2014, 52(3): 45-49.
[14] 朱发梅, 郑家法, 谢鼎华, 胡鹏. 5个大前庭水管综合征家系SLC26A4基因的检测分析[J]. 山东大学学报(医学版), 2014, 52(10): 90-95.
[15] 孙瑾,韩波,魏美丽,杨文巍,王介忠,刘永蛟. 动脉导管未闭患儿TFAP2B基因变异筛查[J]. 山东大学学报(医学版), 2013, 51(3): 72-75.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!